Belite Bio, Inc
BLTEHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeBelite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. The $6.02B market capitalization puts BLTE squarely in mid-cap range for its industry. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients.
Market Cap
$6.02B
Beta
-1.23
P/E (TTM)
—
P/E (Fwd)
158.93
EPS (TTM)
$-2.52
EPS (Fwd)
$0.94
ROE
-18.9%
ROA
-13.0%
Cash
—
Total Debt
$0
Free CF
—
52W Change
146.4%
Annual Financials
Cash vs Debt
Belite Bio, Inc carries $0 in total debt, a figure that investors should evaluate relative to the company's earnings power. ROE of -18.9% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With a beta below 0.7, Belite Bio, Inc typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Belite Bio, Inc and its sector.